Investor Information

33rd Annual J.P. Morgan Healthcare Conference
Jan 13, 2015 at 12:00 PM ET

ImmunoGen 2Q FY2015 quarterly release
Jan 30, 2015 at 6:30 AM ET

ImmunoGen 2Q FY2015 quarterly conference call
Jan 30, 2015 at 8:00 AM ET

IMGN (Common Stock)
Exchange NASDAQ GS
Price 6.11
Change (%) Stock is Down 4.74 (43.687%)
Volume 16,043,400
Data as of 12/19/14 4:00 PM
Minimum 20 minute delay Refresh quote

Corporate Profile

ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's antibody-drug conjugate (ADC) technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells; the Company has also developed antibodies with anticancer activity of their own. The first product approved with ImmunoGen's ADC technology is Roche's Kadcyla®. ImmunoGen has three wholly owned product candidates in clinical testing, with eight additional compounds in the clinic through the Company's partnerships with Amgen, Bayer HealthCare, Biotest and Sanofi. More information about ImmunoGen can be found at

Shareholder Inquiries

Inquiries related to the Company may be directed to the Investor Relations department at our headquarters. Communications related to stock and transfer requirements, including lost stock certificates and change of name or address, should be directed to the Transfer Agent.

Corporate Headquarters

ImmunoGen, Inc.
830 Winter Street
Waltham, MA 02451-1477
Phone: (781) 895-0600

Transfer Agent and Registrar

Broadridge Corporate Issuer Solutions, Inc.
P.O. Box 1342
Brentwood, NY 11717
Phone: (877) 830-4936
Fax: (215) 553-5402

Corporate Counsel

Mintz, Levin, Cohn, Ferris,
Glovsky and Popeo, P.C.
Boston, MA

Independent Accountants

Ernst & Young LLP
Boston, MA

Receive E-mail AlertsE-mail Alert Icon

Sign up to receive e-mail alerts whenever ImmunoGen, Inc. posts new information to the site. Just enter your e-mail address and click Submit.

Quotes delayed at least 20 minutes. Market data provided by eSignal.